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Key Points
•Baseline maximum
tumor diameter is an
important predictor of
relapse for patients with
ES-HL achieving
complete metabolic
remission.
• Patients with baseline
tumor size $5 cm have
worse outcomes with
ABVD alone and are
likely to benefit from
consolidation
radiotherapy.
Introduction
The high cure rates achieved in early-stage (ES) Hodgkin lymphoma (HL) are one of the great successes
of hemato-oncology, but late treatment-related toxicity undermines long-term survival. Improving
overall survival and quality of life further will require maintaining disease control while potentially de-
escalating chemotherapy and/or omitting radiotherapy to reduce late toxicity. Accurate stratification of
patients is required to facilitate individualized treatment approaches. Response assessment using 18
F-fluorodeoxyglucose positron emission tomography (PET) is a powerful predictor of outcome in HL,1,2
and has been used in multiple studies, including the United Kingdom National Cancer Research
Institute Randomised Phase III Trial to Determine the Role of FDG–PET Imaging in Clinical Stages
IA/IIA Hodgkin’s Disease (UK NCRI RAPID) trial, to investigate whether patients achieving complete
metabolic remission (CMR) can be treated with chemotherapy alone.3-5 These PET-adapted trials have
demonstrated that omitting radiotherapy results in higher relapse rates, but without compromising
overall survival.3-5
For the 75% of patients who achieved CMR in RAPID, neither baseline clinical risk stratification
(favorable/unfavorable) nor PET (Deauville score 1/2) predicted disease relapse; additional biomarkers
are needed.1 Tumor bulk has long been recognized as prognostic in HL,1,6 but there remains uncertainty
about the significance and definition of bulk in the era of PET-adapted treatment.7 We performed
a subsidiary analysis of RAPID to assess the prognostic value of baseline maximum tumor dimension
(MTD) in patients achieving CMR.
Methods
We have previously reported the RAPID trial design, primary results, and outcomes according to
pretreatment risk stratification and PET score.1,3 Patients were aged 16 to 75 years with untreated
ES-HL and without B-symptoms or mediastinal bulk (mass. 1/3 internal mediastinal diameter at T5/6).6
Metabolic response after 3 cycles of ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and
dacarbazine) was centrally assessed using PET (N 5 562). Patients with CMR (ie, Deauville score 1-2)
were randomly assigned to receive involved field radiotherapy (IFRT; n 5 208) or no further therapy
(NFT; n 5 211). PET-positive patients (score, 3-5; n 5 143) received a fourth cycle of ABVD and IFRT.
Baseline disease assessment was performed by computed tomography, and bidimensional target lesion
measurements were reported by local radiologists in millimeters. The association of baseline MTD with
HL-related event-free survival (EFS: progression or HL-related death) and progression-free survival
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(PFS) (progression or any-cause death) was assessed using Kaplan-
Meier and Cox regression analyses. Non-HL deaths were either
related to primary treatment toxicity or occurred in HL remission.1
United Kingdom ethical approval for the RAPID trial was via the UK
Multicentre Research ethics committee.
Results and discussion
Baseline patient characteristics have been previously described.1
Median age was 34 years (range, 16-75 years); 184 (37.4%) of 492
patients had unfavorable risk by European Organisation for Research
and Treatment of Cancer criteria, and 155 (32.3%) of 480 by
German Hodgkin Study Groupcriteria. Median MTD for patients
achieving CMR was 3.0 cm (interquartile range, 2.0-4.0 cm) and
3.0 cm (interquartile range, 1.8-4.5 cm) in the NFT and IFRT groups,
respectively, whereas PET-positive patients had a median MTD of
3.9 cm (interquartile range, 2.8-5.1 cm). After a median follow-up of
61.6 m, 44 HL progression events occurred: 21 NFT, 9 IFRT and 14 PET-
positive. No patient received salvage treatment without docu-
mented progression. Only 5 HL-related deaths occurred (1 IFRT, 4
PET-positive), and 12 non-HL deaths (4 NFT, 6 IFRT, 2 PET-positive).1
For patients with CMR (N 5 419), there was a strong association
between MTD and EFS (hazard ratio [HR], 1.19; 95% confidence
interval [CI], 1.02-1.39; P5 .02), adjusting for treatment group, with
an approximate 19% increase in HL risk per centimeter increase in
MTD. The association was similar in both treatment groups (NFT
HR, 1.20 [95% CI, 0.99-1.44; P 5 .06]; IFRT HR, 1.19 [95% CI,
0.92-1.55; P 5 .19]). The observed effect sizes did not markedly
change after adjusting for baseline clinical risk factors, and similar
results were observed for PFS (supplemental Table 1). In contrast,
for PET-positive patients, there was no association between MTD
and EFS (HR, 0.88; 95% CI, 0.70-1.11; P5 .29) or PFS (HR, 0.87;
95% CI, 0.70-1.08; P 5 .21).
In an exploratory analysis within the NFT group, MTD was dichot-
omized using increasing 1-cm intervals to investigate the relation-
ship between MTD thresholds and EFS. The largest effect size
was observed with an MTD threshold of $5 cm (Table 1). Similar
results were observed for PFS; this threshold also performed best
in time-dependent receiver operating characteristic curve analyses.
It was not possible to assess MTD thresholds in the IFRT group with
only 9 events. Among all randomized patients, 79 (18.9%) had MTD
of $5 cm, the majority with mediastinal (n 5 43), supraclavicular (n
5 17), or cervical (n5 16) locations. Five-year EFS for patients with
MTD of $5 cm randomly assigned to NFT and IFRT was 79.3%
(n 5 39; 95% CI, 66.6%-92.0%) and 94.9% (n 5 40; 95% CI,
88.0%-100%), respectively (P 5 .03; Figure 1).
This subsidiary analysis of a large, prospective, randomized trial
reinforces the prognostic relevance of tumor size with PET-adapted
treatment. We found a clear association between MTD and EFS for
patients achieving CMR after ABVD that was most evident for those
randomly assigned to NFT, principally as a result of the higher
number of events in this group. A threshold of 5 cm best stratified
risk in RAPID patients receiving chemotherapy alone, acknowledg-
ing the small number of events and a need for validation.
Our findings are consistent with large, pre-PET studies in ES-HL8
and relapsed HL,9 in which MTD of $5 cm was an adverse prog-
nostic factor. This is a more conservative risk threshold than con-
ventional definitions of bulk,10 and a recently proposed threshold of
7 cm for ES-HL.7 Because of the exclusion of patients with B
symptoms and mediastinal bulk, few patients had MTD of above
7 cm inRAPID,with a limited number of events to assess the significance
of higher MTD cutoffs, although there was evidence of an association
between risk and increasing MTD as a continuous variable.
Because of the small number of events in the IFRT group, it remains
unclear whether radiotherapy can overcome the prognostic in-
fluence of MTD. However, excellent outcomes were achieved for
patients in CMR with MTD of $5 cm who received IFRT. PET
positivity as an indicator of chemotherapy resistance may override
the earlier influence of baseline MTD on EFS and explain the lack of
association between MTD and EFS in PET-positive patients.
Although omitting radiotherapy in ES-HL is accompanied by a small
increase in early relapse, data from randomized trials are too immature
to assess whether this is compensated for by a reduction in late toxicity
or long-term survival difference.3-5 Therefore, it remains contentious
whether radiotherapy should be omitted in selected patients. This study
Table 1. Association between increasing maximum tumor dimension (MTD) thresholds and event-free survival in PET-negative patients
randomly assigned to receive no further therapy (N 5 211)
MTD threshold, mm*
<MTD threshold ‡MTD threshold
HR ‡threshold 95% CI Pn Events n Events
10 20 2 191 19 0.97 0.23-4.19 .97
20 51 4 160 17 1.35 0.45-4.01 .59
30 103 6 108 15 2.43 0.94-6.27 .07
40 151 11 60 10 2.38 1.01-5.61 .05
50 172 12 39 9 3.78 1.59-9.02 .003
60 187 17 24 4 2.00 0.67-5.95 .21
70 198 19 13 2 1.60 0.37-6.88 .53
80 205 19 6 2 3.36 0.77-14.64 .11
90 209 20 2 1 5.56 0.74-41.64 .09
100 210 21 1 0 — — —
Bold text indicates chosen MTD threshold.
*Small numbers of patients and events across some groups.
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demonstrates that patients with CMR can be risk-stratified by MTD
to identify a group of patients for whom chemotherapy alone may be
insufficient. We hypothesize that targeted use of radiotherapy for
patients with CMR and baseline MTD of $5 cm may improve
outcomes, which requires validation in prospective studies.
Personalized treatment approaches will require assessment of
potential radiation toxicity, considering age, sex, and disease site. Of
note, only 43 (54.4%) of 79 disease sites $5cm were mediastinal,
where radiation toxicity is considered to be higher. Meanwhile,
selected patients with MTD smaller than 5 cm and very low risk for
radiation toxicity may benefit from RT.11
The main limitation of this study is that computed tomography scans
were not centrally reviewed. As with most prospective trials, data
were not collected on which image planes were examined.
Therefore, this study provides a real-world assessment of MTD.
In summary, our study demonstrates a striking association between
increasing MTD and relapse risk for patients with ES-HL achieving
CMR. For RAPID patients receiving ABVD alone, a cutoff of$5 cm
best stratified those at highest risk for relapse. These findings will
help inform discussions about the personalized application of RT,
where benefits of radiotherapy are balanced against potential risks.
These findings have informed the design of our follow-on trial to
RAPID, which will prospectively allow involved-site RT consolidation
for patients in CMR with baseline MTD of $5 cm.
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Figure 1. EFS and progression-free survival according to MTD in patients with CMR. (A) Event-free survival. (B) Progression-free survival.
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